{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "CitationSubset": ["IM"], "OtherAbstract": [], "KeywordList": [["COPD pharmacology", "asthma pharmacology", "inhaler devices"]], "GeneralNote": [], "OtherID": [], "InvestigatorList": [], "PMID": "31699805", "DateCompleted": {"Year": "2020", "Month": "08", "Day": "10"}, "DateRevised": {"Year": "2024", "Month": "07", "Day": "23"}, "Article": {"ArticleDate": [{"Year": "2019", "Month": "11", "Day": "07"}], "Language": ["eng"], "ELocationID": ["10.1136/thoraxjnl-2019-213744"], "Journal": {"ISSN": "1468-3296", "JournalIssue": {"Volume": "75", "Issue": "1", "PubDate": {"Year": "2020", "Month": "Jan"}}, "Title": "Thorax", "ISOAbbreviation": "Thorax"}, "ArticleTitle": "Carbon footprint impact of the choice of inhalers for asthma and COPD.", "Pagination": {"StartPage": "82", "EndPage": "84", "MedlinePgn": "82-84"}, "Abstract": {"AbstractText": ["In the 1990s, metered dose inhalers (MDIs) containing chlorofluorocarbons were replaced with dry-powder inhalers (DPIs) and MDIs containing hydrofluorocarbons (HFCs). While HFCs are not ozone depleting, they are potent greenhouse gases. Annual carbon footprint (CO<sub>2</sub>e), per patient were 17\u2009kg for Relvar-Ellipta/Ventolin-Accuhaler; and 439\u2009kg for Seretide-Evohaler/Ventolin-Evohaler. In 2017, 70% of all inhalers sold in England were MDI, versus 13% in Sweden. Applying the Swedish DPI and MDI distribution to England would result in an annual reduction of 550 kt CO<sub>2</sub>e. The lower carbon footprint of DPIs should be considered alongside other factors when choosing inhalation devices."], "CopyrightInformation": "\u00a9 Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ."}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden christer.janson@medsci.uu.se."}], "Identifier": ["0000-0001-5093-6980"], "LastName": "Janson", "ForeName": "Christer", "Initials": "C"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Environment, Health, Safety and Sustainability, GlaxoSmithKline, Brentfor, London, UK."}], "Identifier": [], "LastName": "Henderson", "ForeName": "Richard", "Initials": "R"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Worldwide Medical Affairs Europe Mid Size & Cluster R&D, GlaxoSmithKline, Solna, Stockholm, Sweden."}], "Identifier": [], "LastName": "L\u00f6fdahl", "ForeName": "Magnus", "Initials": "M"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Meteorologist, The Polyfuture Institute SWC AB, Nacka, Sweden."}], "Identifier": [], "LastName": "Hedberg", "ForeName": "Martin", "Initials": "M"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Respiratory Medical Franchise, GlaxoSmithKline, Brentford, London, UK."}], "Identifier": [], "LastName": "Sharma", "ForeName": "Raj", "Initials": "R"}, {"AffiliationInfo": [{"Identifier": [], "Affiliation": "Respiratory Department, East and North Hertfordshire NHS Trust, Stevenage, UK."}], "Identifier": ["0000-0002-1808-3663"], "LastName": "Wilkinson", "ForeName": "Alexander J K", "Initials": "AJK"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Thorax", "NlmUniqueID": "0417353", "ISSNLinking": "0040-6376"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Adrenergic beta-Agonists"}, {"RegistryNumber": "0", "NameOfSubstance": "Fluorocarbons"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Administration, Inhalation"}, {"QualifierName": ["administration & dosage"], "DescriptorName": "Adrenergic beta-Agonists"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Asthma"}, {"QualifierName": [], "DescriptorName": "Carbon Footprint"}, {"QualifierName": [], "DescriptorName": "England"}, {"QualifierName": [], "DescriptorName": "Equipment Design"}, {"QualifierName": [], "DescriptorName": "Fluorocarbons"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Nebulizers and Vaporizers"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Pulmonary Disease, Chronic Obstructive"}, {"QualifierName": [], "DescriptorName": "Sweden"}], "CoiStatement": "Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare the following: CJ reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and TEVA outside the submitted work; MH reports honoraria from GlaxoSmithKline for presenting scientific data on climate change; AJKW has nothing to disclose; RH and RS are GlaxoSmithKline employees and hold GlaxoSmithKline stocks/shares, ML is an employee of GlaxoSmithKline."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "\nUnited Nations \nMontreal protocol on substances that deplete the ozone layer. Available: http://www.un-documents.net/mpsdol.htm [Accessed 7 Nov 2018].", "ArticleIdList": ["0"]}, {"Citation": "Lavorini F, Corrigan CJ, Barnes PJ, et al. . Retail sales of inhalation devices in European countries: so much for a global policy. Respir Med 2011;105:1099\u2013103. 10.1016/j.rmed.2011.03.012", "ArticleIdList": ["10.1016/j.rmed.2011.03.012", "21489771"]}, {"Citation": "\nBritish Thoracic Society \nThe environment and lung health. Available: https://www.brit-thoracic.org.uk/document-library/governance-and-policy-documents/position-statements/environment-and-lung-health-position-statement-2019/ [Accessed 3 May 2019]."}, {"Citation": "\nNHS Digital \nPrescription cost analysis: England, 2017, 2018.  Available: https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/prescription-cost-analysis-england-2017 [Accessed 7 Nov 2018]."}, {"Citation": "\nMontreal protocol on substances that deplete the ozone layer. Report of the UNEP medical technical options Committee, 2014 assessment. Available: http://conf.montreal-protocol.org/meeting/oewg/oewg-36/presession/Background%20Documents%20are%20available%20in%20English%20only/MTOC-Assessment-Report-2014.pdf [Accessed 11 Jan 2019]."}, {"Citation": "\nClimate & Clean Air Coalition \nHydrofluorocarbons (HFC). Available: https://www.ccacoalition.org/fr/slcps/hydrofluorocarbons-hfc [Accessed 19 of Aug 2019]."}, {"Citation": "Wynes S, Nicholas KA. The climate mitigation gap: education and government recommendations miss the most effective individual actions. Environ Res Lett 2017;12 10.1088/1748-9326/aa7541", "ArticleIdList": ["10.1088/1748-9326/aa7541"]}, {"Citation": "Vestbo J, Papi A, Corradi M, et al. . Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 2017;389:1919\u201329. 10.1016/S0140-6736(17)30188-5", "ArticleIdList": ["10.1016/S0140-6736(17)30188-5", "28385353"]}, {"Citation": "\nNHS England sustainable development unit \nReducing the use of natural resources in health and social care 2018 report. Available: https://www.sduhealth.org.uk/policy-strategy/reporting/natural-resource-footprint-2018.aspx [Accessed 20 Jun 2019]."}, {"Citation": "\nBritish Thoracic Society/Scottish Intercollegiate Guidelines Network \nBritish guideline on the management of asthma, 2019.  Available: https://www.brit-thoracic.org.uk/standards-of-care/guidelines/btssign-british-guideline-on-the-management-of-asthma/ [Accessed 14 Dec 2018]."}]}], "History": [{"Year": "2019", "Month": "6", "Day": "24"}, {"Year": "2019", "Month": "8", "Day": "25"}, {"Year": "2019", "Month": "10", "Day": "16"}, {"Year": "2019", "Month": "11", "Day": "9", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "8", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "11", "Day": "9", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "12", "Day": "24"}], "PublicationStatus": "ppublish", "ArticleIdList": ["31699805", "PMC6929707", "10.1136/thoraxjnl-2019-213744", "thoraxjnl-2019-213744"]}}]}